> The Future is Today

Tecnimede Group (GTM)

Tecnimede started in 1980

Privately-owned company

Headcount of 700 employees

130.000.000,00€ turnover in 2015

Tecnimede Group is dedicated to the improvement and preservation of human life

and health, through the development and commercialization of pharmaceutical

products, with a strong focus on quality and technological innovation.

Atlas Pharm Plant (Morocco)

2011

1999

Tecnimede Maroc MKT & Sales

Tecnimede España MKT & Sales

2009

Labor Qualitas Research &

Development Campus

1998

Atlantic Pharma Plant (Sintra/Portugal)

2008

EU GMP’s, Anvisa GMPs (Brésil), Saudi Arabia GMPs, Jordan GMPs

& ISO 9001:2000 compliance

West Pharma Plant

(Lisbon/Portugal)

1995

EU GMP’s & ISO 9001:2000 compliance

2013

Tecnigen (Italy) Atlanticpharma (Brazil)

MKT & Sales

2015

Altadis (Colombia)

MKT & Sales

The history of GTM

1980

Tecnimede MKT & Sales

Atlantic Pharma

• State of art manufacturing plant

• Facilities cover 5.000 m2, implemented in an area of 43 000 m2

• Oral dosage forms, Creams, Ointments, Suppositories, injectables (small volume), Liquids, Suspensions with capacity for more than 30 million packs

• EU GMP’s, Anvisa (Brazil) GMPs, GCC GMPs, Jordanian GMPs & ISO 9001:2000 compliance

West Pharma

• Facilities cover 3 000 m2

• Oral solid dosage forms with capacity for 12 millions pack units

• EU GMP’s & ISO 9001:2000 compliance

The manufacturing capacity of GTM

Atlas

• Facilities cover 3.400 m², implemented within an area of 10.000 m²

• High Potency Active Products in oral solid dosage forms

• Capacity for 4 millions pack unit

• Complying with EU GMP

• Planned certifications: Anvisa (Brazil) GMPs, GCC GMPs, Saudi FDA GMP’s, Jordanian GMP’s, USFDA GMP’s & ISO 9001:2000 compliance

)

The manufacturing capacity of GTM

The strategy of GTM

Inte

rnati

on

al

exp

an

sio

n

Rese

arc

h &

Deve

lop

men

t

Research & Development

(R&D)

The strategy of GTM

The activities in R & D

Group’s Number of Listed Patents (35 patents)

New chemical entities

Alternative processes, New salts

Pharmaceutical Composition

New indications

Among the most innovative companies in Portugal (Ranking by number of patents)

Research of new chemical entities (3 NCEs already patented)

Research of new fixed combinations

Generic drug development (15 files per year)

Development of new synthesis routes

Development of pharmaceutical formulations, including modified release forms and sterile forms

Analytical Process development and validation

Pharmacological screening

Toxicological studies

Clinical studies

Cell Culture

Under EU & ICH regulatory compliance, ISO 17 025 and GLP certification

The activities in R & D

The activities in R & D

New chemical entities

• TM-01 (metabolic disorders)

• TM-02 (prevention and treatment of the Mycobacterium)

• TM-03 (CNS)

Development of Pharmaceutical Formulations

• Development of generic formulations (15 files per year)

• Development of new fixed combinations;

• Development of new formulations (modified release)

Generic formulations: Bioequivalence/ Bioavailability studies

• New therapeutic indications and new fixed combinations: Pre Clinical studies, Phase II and III Clinical studies

• CROs: Anapharm, Algorithme, Biopharma (Clinical part); Anapharm Europe (Analytical Part)

• 45 scientific publications in peer-review journals

The activities in R & D

Universities of Pharmacy in Portugal

Universities of Pharmacy in Spain

Universities of Pharmacy in Italy

Unique collaboration with the University of Coimbra and its research centers

UC/Tecnimede – nonprofit research organization (50:50) that conducts contract research and development for Tecnimede and other partners

UpCells – the first unit for Advanced Therapies designed in GMP standards (Good Manufacturing Practice), for handling and obtaining vaccines based on dendritic cells and natural killer cells for the treatment of various cancers and autoimmune diseases.

The investments made in R&D activities enabled Tecnimede Group's entry in 26th place on the list of national companies that in 2011 invested the most in R&D.

More than 80 people working in R&D with a background on life sciences, chemistry and engineering

More than 45 scientific articles and posters published in peer-review journals

The investments in R & D

NET INVESTMENT - R&D (thousand euros)

0 2.000 4.000 6.000 8.000

10.000 12.000 14.000 16.000 18.000

2012 2013 2014 2015 2016*

Regulatory compliance with EU / ICH, ISO 17025 and GLP certification

The investments in R & D

• Total area: 3000 m2

• Laboratory area: 1500m2

• Including facilities for development of high potency compounds

Campus I&D do GTM QUINTA DA CERCA

CAIXARIA DOIS PORTOS

PORTUGAL

The strategy of GTM

International Expansion

14

Tecnimede Maroc

• Started in 1999

• Number of molecules: 49

• Total turnover in 2015: 13 million Euro

• Headcount of 82 employees

• Partnerships with local companies: Sothema, Zenith Pharma, Afric-Phar

Tecnimede España

• Started in 2009 - Marketing and Sales

• Number of molecules: 79

• Total turnover in 2015: 15.5 million Euro

• Headcount of 40 employees

International Operations >>>branches

Tecnimede Italie

• Started in 2014 - Jully - Marketing and Sales

• Number of molecules: 50

• Total turnover in 2015: 3 million Euro

• Headcount of 25 employees

International Operations >>>branches

2014 : Brazil

Espagne Italy

Morocco

2015 : New branch in Colombia

+ 100 Countries

+ 1.409 MA’s granted or in evaluation

+ 80 different molecules

International Operations >>>License-out

Currently with sales

International Operations >>>Europe

Albania

Austria

Belgium

Belarus

Bosnia Herzegovina

Bulgaria

Cyprus

Czech Republic

Croatia

Denmark

Finland

France

Georgia

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Lithuania

Luxemburg

Macedonia

Moldova

Netherlands

Poland

Romania

Russia

Serbia

Slovakia

Spain

UK

Ukraine

19

International Operations >>>Other Territories

Currently with sales Futures Sales

(ongoing registrations)

Algeria

Angola

Australia

Azerbaijan

Caribbean Countries

Chile

Colombia

Ecuador

Hong-Kong

Iraq

Lebanon

Macao

Morocco

Mozambique

Peru

Singapore

Sudan

Tunisia

Vietnam

Venezuela

Bahrain

Brazil

CIS Countries

China

Costa Rica

Egypt

Ethiopia

Guatemala

Iran

Jordan

Kuwait

Malaysia

Mexico

New Zealand

Oman

Panama

Pakistan

Philippines

Qatar

Saudi Arabia

South Africa

South Korea

Thailand

Taiwan

UAE

USA

West African Countries

Yemen

Development of new generics: opportunity for creating balanced markets and higher access to products

Development of difficult-to-make products: biosimilars, new oral release solid forms and depot injectables

Basic research oriented to clinical unmet needs: Neurosciences, Tuberculosis and Pain

Modernization of existing infrastructures

New infrastructures: New robotic warehouse

The strategy of GTM – the near future

Accelerate International Expansion: Obtain GMP certification for new plant – Atlas – with relevant world authorities

Partnerships with International companies: networking and technology exchange

The strategy of GTM – the near future

Thank you!

More information at www.tecnimede.com

TECNIMEDE, S.A.

Rua da Tapada Grande nº 2

Abrunheira - 2710-089 Sintra, Portugal

Tel.: 351.21.0414100

Fax: 351.21.9410839